Moderna Collaboration and License Agreement - Narratives (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2022 USD ($) representative product target	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) obligation	Sep. 30, 2022 USD ($)
Moderna Collaboration and License Agreement
Research and development services as collaboration revenues		$ 3,827	$ 2,578	$ 10,630	$ 6,103
Collaboration and License Agreement | Research and Development Services
Moderna Collaboration and License Agreement
Upfront payment	$ 45,000
Variable consideration	$ 73,900
Term of contract	5 years
Noncurrent portion of deferred revenue	$ 45,000
Collaboration and License Agreement | Moderna
Moderna Collaboration and License Agreement
Maximum of Research Targets | target	12
Number of representatives from each company in joint steering committee | representative	3
Collaboration and License Agreement | Moderna | Research and Development Services
Moderna Collaboration and License Agreement
Upfront non-refundable payment received	$ 45,000
Minimum commitment to reimburse research and development costs	$ 10,000
Period of reimbursement of research and development costs	3 years
Number of products developed and commercialized | product	12
Number of performance obligations | obligation				2
Collaboration and License Agreement | Moderna | Minimum | Research and Development Services
Moderna Collaboration and License Agreement
Amount receivable per product	$ 247,000
Collaboration and License Agreement | Moderna | Maximum | Research and Development Services
Moderna Collaboration and License Agreement
Amount receivable per product	$ 253,000
Moderna License Agreement
Moderna Collaboration and License Agreement
Collaboration revenues				$ 20,400